Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Altimmune Inc (NQ: ALT )

7.140 +0.100 (+1.42%)
Streaming Delayed Price Updated: 1:46 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Altimmune Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Nasdaq Surges 100 Points; Crude Oil Rises 2%
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Wednesday. 
Via Benzinga
Twilio (TWLO) Stock Gains 6% on Layoff News
Twilio (TWLO) stock is rising on Wednesday after the programmable communication tools company revealed plans to lay off employees. 
Via InvestorPlace
Nucor, Altimmune And Some Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data
Altimune (ALT) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning. 
Via InvestorPlace
US Stocks Open Higher, Producer Prices Decline for 2nd Month
U.S. stocks traded higher this morning, following the release of PPI data for August. 
Via Benzinga
Altimmune Shares Fall Despite Fatty Liver Disease Study Meets Primary Goal
Via Benzinga
Altimmune: Q1 Earnings Insights
Altimmune (NASDAQ:ALT) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Altimmune: Q4 Earnings Insights
Altimmune (NASDAQ:ALT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Altimmune Stock Is Tanking: What's Going On?
Altimmune Inc (NASDAQ: ALT) shares are falling Wednesday morning. The company announced topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
Not all shares are slowing down alongside the industry group. 
Via Investor's Business Daily
B. Riley Securities Maintains Buy Rating for Altimmune: Here's What You Need To Know
  B. Riley Securities has decided to maintain its Buy rating of Altimmune (NASDAQ:ALT) and raise its price target from $21.00 to $26.00. Shares of Altimmune are trading up 23.53% over the last 24... 
Via Benzinga
Altimmune's Earnings Outlook
Altimmune (NASDAQ:ALT) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
The FDA has cleared Altimmune Inc's (NASDAQ: 
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday
  WeTrade Group, Inc. (NASDAQ: WETG) jumped 46% to $20.56 after the company announced it entered into a sales agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know
Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00. Shares of Altimmune are trading down 0.57% over the last 24... 
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
69 Biggest Movers From Yesterday
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday. 
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital. 
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
Altimmune Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q4, Altimmune (NASDAQ:ALT) posted sales of $3.28 million. Earnings were up 28.71%, but Altimmune still reported an overall loss of $23.89... 
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (... 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.